Earnings Call · Q4 FY2024·2025-02-27

Q4 24EPS +6.71%·Rev n/aQ3 24EPS +36.30%·Rev n/aQ2 24EPS +32.08%·Rev n/aQ1 24EPS +44.58%·Rev n/a⚠ consensus missing

LIGAND PHARMACEUTICALS INC LGND

Melanie Herman — Investor Relations or Corporate Communications (inferred from context)

Todd Davis — Chief Executive Officer

Paul Hadden — President

Tavo Espinoza — Chief Financial Officer

Lauren Hay — Head of Commercial Operations or similar (inferred from context)

+0.6%1d on move date+2.2% vs SPY3d−2.5%5d+0.3%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more LGND calls or request research access.

More LGND calls Browse calls Request research access